Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy [Seeking Alpha]
UCB SA UNSP/ADR (UCBJY)
NASDAQ:AMEX Investor Relations:
ucb.com/investors
Company Research
Source: Seeking Alpha
15min Summary UCB SA's solid buy case is driven by Bimzelx's impressive performance and robust financials despite a temporary 19% EBITDA decline due to product launch investments. Bimzelx, approved for psoriasis and hidradenitis suppurativa, is forecasted to become a blockbuster, potentially generating over €6 billion in peak sales. UCB maintains solid EBITDA margins and a healthy net debt-to-EBITDA ratio of 1.6x, providing financial stability and supporting future earnings growth. While bullish on UCB SA, potential regulatory roadblocks for Bimzelx could impact future growth despite the stock's strong performance in 2024. SweetBunFactory UCB SA OTCPK:UCBJF ), a global biopharmaceutical leader focused on neurology and immunology, is dedicated to providing treatments for patients with severe diseases. Founded in Belgium in 1928, the company reported revenues of €5.25 million and an Adjusted EBITDA of €1.349 million in While UCB experienced strong revenue growth in the
Show less
Read more
Impact Snapshot
Event Time:
UCBJY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UCBJY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UCBJY alerts
High impacting UCB SA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
UCBJY
News
- UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis SuppurativaPR Newswire
- New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis [Yahoo! Finance]Yahoo! Finance
- New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial SpondyloarthritisPR Newswire
- Genascence Appoints Jeymi Tambiah as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific SessionPR Newswire